Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways

The review highlighted the anticancer potential of myricetin, a flavonoid, through its modulation of inflammation and signal transduction pathways. Myricetin was shown to inhibit cancer progression by affecting angiogenesis, cell proliferation, metastasis, and apoptosis across various cancer types, including ovarian, prostate, and lung cancers. It enhanced the efficacy of existing anticancer drugs and demonstrated synergistic effects with treatments like cisplatin and enzalutamide. Despite its promising role, challenges such as poor bioavailability and targeted delivery needed to be addressed. The review suggested further research into myricetin derivatives and nanoformulations to improve its therapeutic application, emphasizing its potential as a natural compound for cancer prevention and treatment.